These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26312673)

  • 1. Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent.
    Quaresma MV; Bernardes Filho F; Hezel J; Peretti MC; Kac BK; Azulay-Abulafia L
    An Bras Dermatol; 2015; 90(3 Suppl 1):51-4. PubMed ID: 26312673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
    Heaphy MR; Albrecht J; Werth VP
    Arch Dermatol; 2005 Jun; 141(6):699-702. PubMed ID: 15967915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris.
    Werth VP; Fivenson D; Pandya AG; Chen D; Rico MJ; Albrecht J; Jacobus D
    Arch Dermatol; 2008 Jan; 144(1):25-32. PubMed ID: 18209165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
    Sami N; Qureshi A; Ruocco E; Ahmed AR
    Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dapsone in the treatment of pemphigus vulgaris.
    Haim S; Friedman-Birnbaum R
    Dermatologica; 1978; 156(2):120-3. PubMed ID: 620865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Childhood pemphigus vulgaris treated with dapsone: a case report.
    Bjarnason B; Skoglund C; Flosadóttir E
    Pediatr Dermatol; 1998; 15(5):381-3. PubMed ID: 9796590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Dapsone in the Treatment of Pemphigus Vulgaris: A Single-Center Case Study.
    Baum S; Debby A; Gilboa S; Trau H; Barzilai A
    Dermatology; 2016; 232(5):578-585. PubMed ID: 27698327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfone syndrome in a patient receiving steroids for pemphigus.
    Barnard GF; Scharf MJ; Dagher RK
    Am J Gastroenterol; 1994 Nov; 89(11):2057-9. PubMed ID: 7942736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IgA pemphigus of the subcorneal pustular dermatosis type. Successful therapy with a combination of dapsone and acitretin].
    Monshi B; Richter L; Hashimoto T; Groiß E; Haensch N; Rappersberger K
    Hautarzt; 2012 Jun; 63(6):482-6. PubMed ID: 22218566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do safe and effective treatment options exist for patients with active pemphigus vulgaris who plan conception and pregnancy?
    Lehman JS; Mueller KK; Schraith DF
    Arch Dermatol; 2008 Jun; 144(6):783-5. PubMed ID: 18559770
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab: A Review in Pemphigus Vulgaris.
    Frampton JE
    Am J Clin Dermatol; 2020 Feb; 21(1):149-156. PubMed ID: 31838645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dapsone in the treatment of pemphigus and pemphigoid: analysis of current data.
    Gürcan HM; Ahmed AR
    Am J Clin Dermatol; 2009; 10(6):383-96. PubMed ID: 19824739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris.
    Mittmann N; Chan B; Knowles S; Mydlarski PR; Cosentino L; Shear N
    J Cutan Med Surg; 2006; 10(5):222-7. PubMed ID: 17234105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of pemphigus vulgaris with etanercept in four patients.
    Shetty A; Marcum CB; Glass LF; Carter JD
    J Drugs Dermatol; 2009 Oct; 8(10):940-3. PubMed ID: 19852124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of stratifying initial dose of corticosteroids by severity of pemphigus vulgaris on long-term disease severity.
    Lyakhovitsky A; Baum S; Scope A; Amichai B; Barzilai A; Rimer J; Trau H
    Int J Dermatol; 2011 Aug; 50(8):1014-9. PubMed ID: 21781080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
    Vyas N; Patel NS; Cohen GF
    J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of chlorambucil with prednisone in the treatment of pemphigus.
    Shah N; Green AR; Elgart GW; Kerdel F
    J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):85-8. PubMed ID: 10607325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lip cyanosis in dapsone therapy: should the dosage be reduced?].
    Stichtenoth D
    MMW Fortschr Med; 2012 Apr; 154(6):32. PubMed ID: 22642026
    [No Abstract]   [Full Text] [Related]  

  • 19. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols.
    Femiano F; Gombos F; Scully C
    J Eur Acad Dermatol Venereol; 2002 Jul; 16(4):353-6. PubMed ID: 12224691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
    Werth VP
    Arch Dermatol; 1996 Dec; 132(12):1435-9. PubMed ID: 8961871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.